Skip to main content
. Author manuscript; available in PMC: 2022 Sep 1.
Published in final edited form as: Nat Med. 2022 Mar;28(3):427–428. doi: 10.1038/s41591-022-01684-8

Table 1.

Outstanding questions for pathology studies of COVID-19

1. Can biomarkers be identified and used to predict progression to severe COVID-19?
2. Are COVID-19 coagulopathies due to pre-existing systemic endotheliopathies or a cause of them?
3. Are there thresholds that pertain to viral loads, viral byproducts and/or respiratory epithelial tissue damage beyond which severe or fatal disease progresses?
4. What therapies might be identified to preempt or blunt damage from COVID-19-related damage cascades initiating downstream severe or fatal endotheliopathies and coagulopathies?
5. After apparent recovery from COVID-19, will recovered individuals show an increased risk of strokes, pulmonary, renal, and cardiac failures in the following years?